regadenozon - risultati della ricerca

Unione Europea - italiano - EMA (European Medicines Agency)

rilonacept regeneron (previously arcalyst)

regeneron uk limited - rilonacept - cryopyrin-sindromi periodiche associate - immunosoppressori - rilonacept regeneron è indicato per il trattamento delle sindromi periodiche associate alla criopirina (caps) con sintomi gravi, tra cui sindrome familiare di autoinfiammatorie fredda (fcas) e la sindrome di muckle-wells (mws), negli adulti e bambini dai 12 anni e più vecchi.

Unione Europea - italiano - EMA (European Medicines Agency)

rapiscan

ge healthcare as - regadenoson - imaging della perfusione miocardica - terapia cardiaca - questo medicinale è solo per uso diagnostico. rapiscan è un selettivo vasodilatatore coronarico per l'uso come un farmaco agente di stress per la scintigrafia miocardica perfusionale (mpi) in pazienti adulti in grado di sottoporsi a un adeguato esercizio fisico stress.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

rapiscan 400 µg/ 5 ml soluzione iniettabile

ge healthcare ag - regadenosonum - soluzione iniettabile - regadenosonum 400 µg, dinatrii phosphas, natrii dihydrogenophosphas, propylenglycolum 750 mg, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 5 ml corresp. natrium 19 mg. - seguito di un vasodilatatore, invece di stressübungen per myokardperfusionsaufnahmen con radionuclidi viene applicato. - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, cellule squamose - agenti antineoplastici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.